Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ersodetug · RZ-358, XOMA-247

Monoclonal antibody · Antagonist of insulin receptor (INSR)

Phase 3 Most advanced trial
4 Registered trials

What is Ersodetug?

Ersodetug is a fully human IgG2 monoclonal antibody that binds the insulin receptor (INSR) and allosterically reduces INSR-mediated signaling by insulin and related hormones such as IGF-2. It is being studied in tumor hyperinsulinism and congenital hyperinsulinism, conditions causing hypoglycemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RZ-358, XOMA-247
Drug type
Monoclonal antibody
Targets
insulin receptor (INSR)
Mechanism
Antagonist of insulin receptor (INSR)
Pathways
insulin receptor signaling, IGF-2 signaling
Therapy area
Gastroenterology, Metabolic
In trials of
RZLT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
QD87BSP58N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06881992 Phase 3 Tumor Hyperinsulinism (Tumor HI) Recruiting RZLT
NCT06208215 Phase 3 Congenital Hyperinsulinism Active not recruiting RZLT
NCT04538989 Phase 2 Congenital Hyperinsulinism Completed RZLT
NCT07262970 N/A Tumor-associated Hyperinsulinism (Tumor HI) Available RZLT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Tumor Hyperinsulinism (Tumor HI)Congenital HyperinsulinismTumor-associated Hyperinsulinism (Tumor HI)

Other drugs acting on INSR

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.